Q&A with Novartis and IQVIA Study Start-Up Leaders

Origin: Novartis, IQVIA Research & Development Solutions, IQVIA Technologies

Launching clinical trials has always been a painstaking process between research sites and pharmaceutical sponsors. But for the last several years, the time between protocol approval and study activation has increased dramatically. Delayed trials may lead to unrecoverable revenues and reduced return on investment, so companies are looking for ways to combat this trend.

IQVIA Technologies explored creative solutions to this problem in Practical Approaches to Faster Study Start-Ups: Making Progress in the Face of Industry Headwinds. Contributors to the webinar included Raphaëlle Gilg of Novartis Pharmaceuticals, Kerry Randall and Rodrigo Guimarães of IQVIA Research and Development Solutions (RDS), and Rosemary Shirey of IQVIA Technologies. Together, they shared their extensive experience and gave practical guidance. This article summarizes their responses to a wide range of questions from a highly engaged audience, including the following:

• How can sites and sponsors partner to accelerate study start-ups?
• How do you keep up energy and momentum throughout site activation, internally and with sites, despite the complicated deliverables involved?
• How do you work with sites to move tasks up to earlier in the timeline to activate ASAP?